Nunzia Balzano
Naples, 80138, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Diet-Induced Ceramide Remodeling as a Mechanistic Link to Cardiac Metabolic Dysfunction.
Journal: Nutrients
Published: June 03, 2026
Volatilomics insights in older adults with diabetes: from metabolic mechanisms to precision geriatric medicine.
Journal: Diabetes research and clinical practice
Published: December 22, 2025
Age-related adiponectin resistance in human skeletal muscle dysfunction: in vivo and in vitro evidence.
Journal: Journal of translational medicine
Published: December 18, 2025
Cardioprotective mechanism of ω-3 fatty acid icosapent ethyl (IPE) in cardiomyocytes: role in high glucose and shear stress-induced mechano-transduction dysregulation.
Journal: Cardiovascular diabetology
Published: October 08, 2025
Safety profile of fentanyl with different routes of administration: a disproportionality analysis using the EudraVigilance database.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: August 28, 2025
Hypogammaglobulinemia in patients with multiple sclerosis receiving disease modifying therapies: disproportionality analysis using the EudraVigilance database.
Journal: Expert opinion on drug safety
Published: April 16, 2025
Lymphopenia associated with sphingosine 1-phosphate receptor modulators (S1PRMs) in multiple sclerosis: analysis of European pharmacovigilance data.
Journal: Pharmacological reports : PR
Published: January 09, 2025
T-cell malignancies following CAR T-Cell therapy: insights from the FDA Adverse Event Reporting System (FAERS).
Journal: Expert opinion on drug safety
Published: December 19, 2024
Risk of Rhabdomyolysis Associated with Dexmedetomidine Use over the Past 10 Years: Insights from the EudraVigilance Database.
Journal: Journal of personalized medicine
Published: August 05, 2024
Pharmacovigilance study on the reporting frequency of atrial fibrillation with immune checkpoint inhibitors: insights from FDA Adverse Event Reporting System.
Journal: Therapeutic advances in drug safety
Published: June 12, 2024
Real-World Safety Data of the Orphan Drug Onasemnogene Abeparvovec (Zolgensma®) for the SMA Rare Disease: A Pharmacovigilance Study Based on the EMA Adverse Event Reporting System.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: February 26, 2024
Last Updated: 09/26/2026